Comparison · NCT04932096-2f7a123f
Melatonin vs Placebo: Adherence Quantitative
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Melatonin vs Placebo: Adherence Quantitative. Trial comparisons, record NCT04932096-2f7a123f. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04932096-2f7a123f
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.889 | 0.565 | 0.98 | wilson | |
| Risk in group 2 | 0.778 | 0.453 | 0.937 | wilson | |
| Risk difference, group 1 minus group 2 | 0.111 | -0.25 | 0.449 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.14 | 0.752 | 1.74 | log | |
| Odds ratio, group 1 over group 2 | 2.29 | 0.169 | 31 | log | |
| Number needed to treat, for one more participant with the outcome on Melatonin than on Placebo | 9 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Melatonin | (melatonin doses of 3mg or 5mg based on patient size given nightly 1 hour prior to bedtime every night for 30 days)~melatonin: melatonin supplementation | 8 | 9 | OG000 |
| Group 2 | Placebo | Placebo~placebo: microcrystalline cellulose filled capsule | 7 | 9 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Adherence Quantitative
- Description
- pill counts, report of using study medication at least 5/7 days per week
- Time frame
- 1-month
- Population
Source ClinicalTrials.gov
Trial
- Title
- Sleep Management And Recovery After Traumatic Brain Injury in Kids: Pilot Intervention of Melatonin
- NCT number
- NCT04932096
- Phases
- PHASE2
- Conditions
- Traumatic Brain Injury, Critical Illness, Sleep
- Interventions
- melatonin, placebo
- Lead sponsor
- Oregon Health and Science University
- Results first posted
- 2025-08-20
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04932096?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04932096-2f7a123f